Krystal Biotech Reports $119.2 Million in VYJUVEK Revenue for Second Quarter 2026
The gene therapy specialist's flagship product has generated nearly $1 billion in cumulative sales since its commercial launch.
Quarterly Revenue Milestone
Krystal Biotech, Inc. (NASDAQ: KRYS) announced second quarter 2026 financial and operating results on August 3, reporting $119.2 million in global revenue for VYJUVEK during the period. The Pittsburgh-based gene therapy company disclosed that its flagship product has now generated $965.9 million in cumulative sales since its commercial launch.
The $10 billion market cap biotechnology firm released its quarterly results through both GlobeNewswire and SEC EDGAR filings, with shares last trading at $341.12.
VYJUVEK Performance
VYJUVEK, Krystal Biotech's gene therapy for dystrophic epidermolysis bullosa (DEB), continues to serve as the company's primary revenue driver. The second quarter performance brings the company's cumulative sales to nearly the $1 billion threshold, marking a significant commercial milestone for a rare disease treatment.
Insider Activity and Upcoming Events
Recent regulatory filings show insider activity from Thomas John Charles, who exercised options for 1,000 shares on two separate occasions and subsequently sold 1,000 shares, according to MarginX data.
The company is scheduled to hold its Q2 2026 earnings call on August 3, 2026, where management is expected to provide additional details on the quarter's performance and operational progress.
Broader Market Context
Investors will be monitoring broader monetary policy developments in the coming months, with the Federal Reserve's Federal Open Market Committee scheduled to announce rate decisions on September 16 and October 28, 2026, according to MarginX data. These macroeconomic events could influence sentiment across the biotechnology sector.
Krystal Biotech operates in the United States and has established itself as a commercial-stage gene therapy company focused on developing treatments for rare diseases with significant unmet medical needs.
This article was generated by MarginX from public news on 2026-08-03. It is not investment advice.